It is common for critical care nurses to administer sedative medications to patients receiving mechanical ventilation. Although patient-controlled analgesia is frequently used in practice to promote effective selfmanagement of pain by patients, it is not known if patient-controlled sedation can be used to promote effective self-management of distressing symptoms associated with mechanical ventilation. A randomized pilot trial was conducted to evaluate whether patient self-administered sedation with dexmedetomidine is safe and acceptable for self-management of anxiety during ventilator support. This case report details the experiences of one patient enrolled in the pilot trial who was randomly assigned to the experimental dexmedetomidine intervention, completed the study protocol, and provided feedback. In a poststudy survey, the patient responded positively to the use of self-administered sedation with dexmedetomidine during ventilator support. (Critical Care Nurse. 2018;38[1]:17-23) T o promote comfort, decrease oxygen consumption, facilitate nursing care, and ensure patient safety, it is common practice for critical care nurses to administer sedative medications to patients receiving mechanical ventilation in the intensive care unit (ICU).
variety of scales to assess pertinent domains related to sedation, such as consciousness, agitation, anxiety, sleep, motor activity, and patient-ventilator synchrony. 9 Although these scales are used in practice to guide sedative administration, consensus is not consistent among nurses on the most appropriate way to use the scores to determine when and how much sedation to administer to achieve optimal sedation levels.
Patient-controlled analgesia has been used in practice for many years to promote patients' effective selfmanagement of pain; however, it is not known if parallel benefits exist when patient-controlled sedation is used to promote effective self-management of anxiety and other distressing symptoms associated with mechanical ventilation. A randomized pilot trial was conducted to evaluate whether self-administered sedation by the patient with dexmedetomidine is safe, feasible, and acceptable for self-management of anxiety during ventilator support.
Dexmedetomidine is an ideal drug for selfadministration of sedation because it has sedative and analgesic properties. Dexmedetomidine has a rapid onset of action and a rapid distribution phase. Based on the pharmacokinetic profile and previous preliminary research of this medication and approach, [10] [11] [12] the dexmedetomidine study protocol was developed to accommodate self-administration every 20 minutes and titration of the basal infusion every 2 hours. Dexmedetomidine's lack of active sedating metabolites makes it preferable to sedation with midazolam in patients with renal dysfunction. 10 In addition, dexmedetomidine does not cause respiratory depression and patients receiving dexmedetomidine can be readily aroused to baseline consciousness with stimulation, allowing for interactions with health care providers and active participation in care. 11 This case report describes the experiences of a patient enrolled in the pilot trial 13 who was assigned to the experimental dexmedetomidine intervention, completed the study protocol, and provided feedback.
Overview of the Randomized Pilot Trial
Alert, adult patients who were intubated and expected to require mechanical ventilation for at least 48 hours were screened for possible enrollment from 3 ICUs in 2 hospitals in Minneapolis, Minnesota. Table 1 lists inclusion and exclusion criteria for the randomized pilot trial of the safety and acceptability of patient-administered sedatives. Additional details on this parent study are reported elsewhere. 13 To avoid selection bias, patients were randomly assigned to 1 of 2 groups, dexmedetomidine (intervention group; n = 17) or usual ICU care (control group; n = 20) after consent was obtained. Subjects enrolled in the control group received no study intervention and continued on their prescribed sedation regimens, which were directed by physician order and administered by nurses, per unit policy. In this specific practice setting, the most common sedation management strategy involved the administration of continuous sedative infusions rather than routine, intermittent sedative boluses.
For patients in the intervention group, the LifeCare PCA Infusion System (Hospira) was used to administer dexmedetomidine in the patient-controlled analgesia plus continuous infusion mode. Patients were given a loading dose of dexmedetomidine (0.5 μg/kg) followed by a continuous basal infusion of 0.2 μg/kg per hour up to a maximum infusion of 0.7 μg/kg per hour. 12, 13 Patients were allowed 3 self-boluses of dexmedetomidine per hour (0.25 μg/kg) with a 20-minute lockout. 12, 13 denied doses, depending on how frequently they pressed the button on the infusion-system device.
Patients in the dexmedetomidine group were instructed to press the push-button device when feeling anxious or if they desired medication for relaxation. Nurses increased or decreased the basal infusion rate based on the number of bolus attempts from the patient in the prior 2 hours. Patients remained in the study for up to 5 days or until they withdrew, were extubated, transferred from the ICU, or died. Acceptability was determined by patients' self-reported satisfaction and ability to administer dexmedetomidine. A 100-mm visual analog scale to assess patients' anxiety was used daily. 14, 15 Conclusions from the pilot trial were positive, indicating self-administering sedative therapy is feasible, acceptable by patients, and safe in that no patients in the dexmedetomidine group self-extubated and none were removed from the study because of adverse safety events. CASE REPORT T he patient in this case report, PD, was chosen because her experience modeled the clinical intent for which the dexmedetomidine intervention was proposed. PD was intubated but was hemodynamically stable and able to interact and follow commands upon study enrollment. PD remained alert and interactive after extubation and was able to describe her experience with the intervention.
PD was a 64-year-old white woman admitted to the surgical ICU from an outside community hospital after developing sepsis and postoperative renal failure after the surgical repair of perforated diverticulitis. Other signifi cant medical history included Lyme disease and an inguinal hernia. PD's severity of illness score (by Acute Physiology and Chronic Health Evaluation III) at the time of ICU admission was 104 (range, 0-299). Vital signs and laboratory values on ICU admission that contributed to the patient's overall severity of illness score are listed in Table 2 .
PD arrived at the unit needing 7 L of oxygen via an reservoir nasal cannula, but she required endotracheal intubation and initiation of mechanical ventilatory support because of respiratory distress secondary to septic shock on the afternoon after her ICU admission.
PD was assessed for study eligibility by research staff on the morning of day 5 of ICU care, which was day 4 of mechanical ventilation. PD was noted to be negative for delirium based on the Confusion Assessment Method for the ICU and had suffi cient strength to press the button on the infusion device. PD consented to participate in the study; she was enrolled and subsequently randomly assigned to the dexmedetomidine group. Continuous midazolam (0.5 mg/h) and hydromorphone (0.2 mg/h) were infusing at the time of study enrollment, as shown in Figure 1 . At that time, PD provided an anxiety rating on the visual analog scale for anxiety of 25 mm (on a 0-100 mm scale).
At 2 PM, PD's continuous midazolam infusion was discontinued, but hydromorphone remained as a continuous infusion, and, per study protocol, PD was given a weight-based loading bolus dose of dexmedetomidine 60 μg, administered over 10 minutes. The continuous dexmedetomidine basal infusion began at 2:10 PM, immediately after the loading bolus dose, and was set at 24 μg/h (0.2 μg/kg per hour). A 20% decrease in heart rate and a 14% decrease in mean arterial pressure were observed after 30 minutes of the continuous dexmedetomidine infusion; however, these fl uctuations remained within the study's established safety protocols during bolus infusion and the initiation of continuous infusion (heart rate range, 65-81/min; mean arterial pressure range, 81-102 mm Hg).
PD's basal infusion rate, as depicted in Figure 2 , was decreased from 24 μg/h to 12 μg/h (0.1 μg/kg per hour) at the end of day 1, per protocol. 12, 13 The continuous dexmedetomidine infusion remained at this rate for the duration of PD's enrollment in the study. The continuous hydromorphone infusion was discontinued during PD's second day on the study protocol. During the study protocol, PD received nurse-administered doses of hydromorphone and midazolam as needed. PD required a total of 5.5 mg of hydromorphone and 5 mg of midazolam during 42.5 hours of being on the dexmedetomidine protocol. The next morning (day 2), PD was reassessed by research personnel, was again noted to be negative for delirium according to the Confusion Assessment Method for the ICU, and had suffi cient strength to press the button of the dexmedetomidine infusion device, making her eligible to remain in the study. PD rated the visual analog scale for anxiety as 15 mm, which was a decrease of 10 mm from the previous day. PD self-administered 3 bolus doses of dexmedetomidine on day 2 and required a single 1-mg dose of midazolam, which was given by nursing staff. PD was extubated at 6:12 AM on day 3, but from midnight to extubation, PD self-administered 8 bolus doses of dexmedetomidine and was denied 4 bolus doses before being extubated around 6 AM, at which time PD was offi cially removed from the study protocol. Additional delirium and anxiety data for day 3 were not gathered, because PD was extubated before research staff could obtain the assessments. After study completion, PD required subsequent doses of lorazepam, as well as 10 additional bolus doses of hydromorphone within 12 hours.
All patients randomly assigned to the dexmedetomidine group were approached by research staff to complete an investigator-developed post-dexmedetomidine satisfaction survey with 3 Likert-scale questions that assessed the patients' ability to self-administer the medication and control anxiety, and their level of relaxation experienced during the protocol. Patients could add free-form comments to each question. PD verbally completed the postdexmedetomidine satisfaction survey on day 3 at 11:30 AM. At the time, PD's continuous hydromorphone infusion had been restarted. She was sitting in a chair and her husband was present in the room. Research staff wrote PD's survey responses verbatim on the post-dexmedetomidine satisfaction survey form. PD rated her ability to self-administer the medication for relaxation, ability to control anxiety, and level of relaxation experienced during the dexmedetomidine protocol all as "very satisfi ed" and provided the following comments: "Absolutely nothing negative," "worked great," "could fi nally concentrate on my breathing," "relaxed enough that I could take a nap," and "such a shame they take it away when you are extubated." Figure 2 Case report: total dexmedetomidine patient received by hour while on study protocol. 
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Discussion
Patients' self-administered sedative therapy with dexmedetomidine is a feasible, safe, and acceptable method of sedative delivery for a select group of patients receiving mechanical ventilation. 13 This case report of PD's experience with an experimental protocol supports the use of dexmedetomidine by patients with a high likelihood of benefiting from this innovative sedation selfmanagement strategy. Dexmedetomidine allowed PD to be interactive yet comfortable in the postoperative period, which advances the goal of current clinical practice guidelines. 8 Of note, nurse-administered supplemental sedative medications were minimal during the protocol enrollment. PD required less midazolam while on the dexmedetomidine protocol compared with preenrollment doses, but once the protocol concluded (after PD was extubated), subsequent doses of lorazepam had to be administered. Narcotic analgesia requirements were stable or slightly decreased while the patient was receiving dexmedetomidine, and after the dexmedetomidine protocol concluded, PD required additional hydromorphone boluses. In addition, PD's visual analog scale for anxiety scores decreased while on the protocol from 25 to 15 mm, suggesting that a lighter level of sedation did not increase PD's analgesic medication needs.
Basic hemodynamic monitoring is essential with any administration of dexmedetomidine, because of potential hypotensive and bradycardic effects from 2 -adrenoreceptor agonists. Although slight fluctuations in PD's heart rate and mean arterial pressure were noted, these values remained within the study's established safety protocols during bolus infusion and the initiation of continuous infusion, and neither of these hemodynamic changes was clinically significant nor did they require intervention. This clinical trial excluded patients with hemodynamic instability, and this protocol would need to be carefully considered and used with extreme caution for patients with acute hypotension and/or bradycardia.
Current clinical practice guidelines 8 provide direction for clinicians about sedation administration for patients receiving mechanical ventilatory support. There is no opportunity for patients themselves to participate in their own sedation management. Although patientcontrolled analgesia has been established as an effective intervention to promote patient self-management of pain, there is little research that has examined the application of this novel approach to sedative self-administration. 16 In a recent study, critically ill patients were asked about their sedation preferences after extubation, and their responses varied; some patients were pleased with their treatment while others desired either more or less sedation. 17 The heterogeneity of their responses demonstrates the importance of considering the individual patient's perception of their sedation needs throughout their critical illness trajectory. 16 In the case report, PD self-administered more sedative medication during both overnight periods. Of note, PD attempted several bolus doses in response to an acute episode of agitation in the overnight hours before extubation. Self-administered dexmedetomidine helped this patient manage acute anxiety, and it took the place of the basal sedation that was being administered before study enrollment. Rather than waiting for a clinician to administer sedative medication for elevated acute anxiety, this patient receiving mechanical ventilation was able to self-administer a bolus dose of dexmedetomidine without delay. Last, PD vividly recalled her experience with self-administration of dexmedetomidine after extubation and rated this method of sedative delivery positively.
Conclusions
Dexmedetomidine shows promise as a drug choice for self-administered sedative therapy in select patients receiving mechanical ventilation in the ICU. 12, 13 In this patient, dexmedetomidine was very well tolerated, providing relaxation and comfort, which resulted in positive remarks from the patient. The clinical course of this patient suggests that dexmedetomidine helped manage individually perceived anxiety in a way that allowed the patient to remain alert, realizing the goal of early extubation and postsurgical recovery. CCN
